ANGIODYNAMICS, INC.
LATHAM, NY

AngioDynamics, Inc., originally founded in Queensbury, New York, in 1988, is a prominent NASDAQ-listed public company known for its emphasis on innovation and expansion within the medical device industry. Operating globally with facilities in North America, Europe, and Asia, AngioDynamics employs approximately 1,400 individuals worldwide. The company's headquarters are strategically located at 14 Plaza Drive, Latham, NY, while it maintains a broad market presence across more than 50 countries. AngioDynamics' initial focus was on research and development of products for interventional radiology, particularly diagnostic catheters and thrombolytic delivery systems. Since becoming publicly traded in May 2004 under the stock symbol ANGO, the company has expanded its product portfolio through strategic acquisitions including RITA Medical Systems, Oncobionic, and Navilyst Medical. These acquisitions have enhanced AngioDynamics' offerings to include radiofrequency ablation, vascular access products, angiographic equipment, dialysis solutions, and targeted renal therapy systems. The company's commitment to innovation is reflected in its mission to serve patients by developing leading therapeutic devices used for minimally invasive treatment of peripheral vascular disease and other conditions. AngioDynamics prides itself on ethical business practices, valuing trust, honesty, and continuous improvement in all professional relationships. The company also emphasizes the importance of providing exceptional customer service, superior product performance, and employee development. AngioDynamics has faced challenges such as a phishing scam involving fake job offers in early 2018 but maintains its focus on strategic growth. Contact information for AngioDynamics can be found at their website, angiodynamics.com, with phone contact available through various international numbers. As an Equal Opportunity/Affirmative Action Employer, AngioDynamics is committed to fostering a diverse and inclusive workplace.